rs147555597
▶GWAS Catalog Trait Associations (45)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
GWAS Catalog Trait Associations (45)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
triglyceride measurement, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele G
OR 0.31
p 4.0e-49
N 115,082
Large GWAS
European
cholesterol:total lipids ratio, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele G
OR 0.30
p 6.0e-44
N 111,638
Large GWAS
European
lipid measurement, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele G
OR 0.28
p 6.0e-42
N 115,082
Large GWAS
European
triglycerides:total lipids ratio, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele G
OR 0.28
p 1.0e-38
N 111,638
Large GWAS
European
blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele G
OR 0.26
p 2.0e-37
N 115,082
Large GWAS
European
phospholipid level, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele G
OR 0.26
p 2.0e-35
N 115,082
Large GWAS
European
free cholesterol measurement, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele G
OR 0.25
p 2.0e-34
N 115,082
Large GWAS
European
VLDL particle size
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele G
OR 0.24
p 6.0e-33
N 115,082
Large GWAS
European
total cholesterol measurement, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele G
OR 0.24
p 4.0e-32
N 115,082
Large GWAS
European
coronary artery disease
van der Harst P et al. “Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease.” Circulation Research 122(3):433-443 (2018)
Allele A
OR 0.40
p 3.0e-31
N 296,525
Large GWAS
This variant is in our database but has no known associations or PRS memberships yet.
Gene information from NCBI Gene. Variant classifications from ClinVar.
Community Wiki
No community notes yet for this variant. Sign in to start one.
Comments
Sign in to join the discussion.
Loading comments…